---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-034906"
form_type: "8-K"
ticker: "BCDA"
cik: "0000925741"
company_name: "BioCardia, Inc."
filed_at: "2024-11-13T23:59:59+00:00"
generated_at: "2026-05-30T01:27:50.001556+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# BioCardia reports Q3 2024 net loss $1.7M; CardiAMP data expected Q1 2025

## Summary
- Net loss $1.7M for Q3 2024 vs $2.6M a year ago; R&D expenses fell to $931K from $1.9M.
- CardiAMP Heart Failure Trial data lock expected Q4 2024, top line results Q1 2025.
- FDA approved protocol amendment for confirmatory Heart Failure II Trial, expanding eligibility.
- Japan's PMDA consultation scheduled for late November 2024 regarding US data-based approval.
- Closed $7.2M upsized public offering in September 2024; FDA cleared steerable introducer sheath for commercial release.

## SEC filing metadata
- accession: 0001437749-24-034906
- form_type: 8-K
- ticker: BCDA
- cik: 0000925741
- company_name: BioCardia, Inc.
- filed_at: 2024-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/925741/000143774924034906/0001437749-24-034906-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/925741/000143774924034906/bcda20241113_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-034906
- JSON: https://secwatch.observer/filing/0001437749-24-034906.json
- Plain text: https://secwatch.observer/filing/0001437749-24-034906.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.